Seattle, WA
November 6-7, 2025

Two Days. One Mission. Transforming Precision Cancer Care.

Seattle, WA
November 6-7, 2025

Precision Pathology & Hematology: Innovations in Cancer Care

Two powerhouse programs—Advancing Pathology Education (APE) and Advancing Precision Oncology (APO)—unified into a single, practice-shaping experience with a special emphasis on hematologic malignancies. Chaired by Jerald Radich, MD (Director, Molecular Oncology Lab) and Cecilia Yeung, MD (Medical Director, Clinical Testing & Molecular Oncology Laboratories) at Fred Hutch Cancer Center, this meeting connects cutting-edge diagnostics to real-world therapeutic decisions.

What this unified program delivers

Diagnostic excellence → treatment impact: Innovations in biomarker testing, AI-powered image analysis, and molecular tools (NGS, IHC, PCR, liquid biopsy) that directly inform care pathways.
Hematologic focus: Genomic profiling, MRD assessment, and next-gen assays transforming leukemia, lymphoma, myeloma, and MDS management.
Case-based learning: Expert-led discussions translating complex results into therapy selection, sequencing, and surveillance.
Team-based workflows: Practical models that integrate pathology, molecular labs, and clinic to accelerate decisions and improve outcomes.

Integrated focus areas

Advancing Pathology Education (APE)
Innovations driving diagnostic precision. Dive into the latest in biomarker testing, AI-driven image analysis, and molecular techniques (NGS, IHC, PCR, liquid biopsy). Elevate reporting quality and turnaround to better guide treatment.

Precision Hematology
Shaping the future of blood cancer care. Apply genomic profiling and MRD to optimize therapy decisions across leukemias, lymphomas, myeloma, and MDS—grounded in expert cases and real-world protocols.

Who should attend

Pathology & Laboratory Medicine: Pathologists, laboratory leaders, molecular scientists, translational researchers.
Clinical Care Teams: Hematologists, oncologists, and multidisciplinary cancer teams (APPs, pharmacists, nurse navigators).

Why join us in Seattle

FREE registration and CME/CE credits (ABPath Continuing Certification via AMA PRA Category 1 Credits™).
Expert keynotes, interactive sessions, and case-based discussions that translate innovation into practice.
Practical, immediately applicable strategies spanning diagnostics through treatment.
High-value networking with clinicians, researchers, and healthcare leaders driving the next era of cancer care.

Seattle is emerging as a hub for life sciences and clinical innovation—join us for two transformative days of education, collaboration, and discovery.

Agenda

Event Partner

November 6,2025
12:00PM	Registration & Check-in
12:00PM	Welcome and Introductions Cecelia Yeung, PhD, Fred Hutch
12:10PM	Breast Cancer – How to Test and Interpret Biomarker Profiles in Breast Cancer
1:00PM	Exhibits/Lunch
1:15PM	Non-CME Session
2:00PM	Lung Cancer – Role of Liquid Biopsy for EGFR Mutations and PD-L1 Expression
2:45PM	Gynecological Cancers – Importance of BRCA Testing in Treatment Planning
3:30PM	Exhibits/Break
4:00PM	Colorectal Cancer – Personalized Treatment Approaches Based on Molecular Profiling
4:45PM	Prostate Cancer – Understanding the Significance of Molecular Testing in Prostate Cancer Progression
5:30PM	Liquid Biopsy and Digital Pathology – Integration of Digital Pathology with Traditional Microscopy
6:00PM	Networking Reception

Learning Objectives

Additional Information Coming Soon

Accreditation Information | TBD CE/CME Credits

Additional Information Coming Soon

November 7, 2025
8:00AM	Registration & Check-in
8:30AM	Welcome and Introductions Jerry Radich, MD, Fred Hutch Cancer Center
8:35AM	A Year of NCI Precision Medicine in AML and MDS (myeloMATCH) Jerry Radich, MD, Fred Hutch Cancer Center
9:05AM	Exhibits/Breakfast
9:50AM	Non-CME Session
10:35AM	Acute Myeloid Leukemia – Clinical Case, Lab, Clinical & Discussion Mary-Beth Percival, MD, Fred Hutch Cancer Center
11:35AM	Myelodysplasia – Clinical Case, Lab, Clinical & Discussion Bart Scott, MD, Fred Hutch Cancer Center
12:35PM	Exhibits/Lunch
12:50PM	Non-CME Session
1:35PM	Acute Lymphoblastic Leukemia – Clinical Case, Lab, Clinical & Discussion Ryan Cassaday, MD, Fred Hutch Cancer Center
2:35PM	Chronic Lymphocytic Leukemia – Clinical Case, Lab, Clinical & Discussion Mazyar Shadman, MD, MPH, Fred Hutch Cancer Center
3:35PM	Exhibits/Break
3:55PM	Myeloma – Clinical Case, Lab, Clinical & Discussion Andrew Portugeuse, MD, Fred Hutch Cancer Center
4:55PM	Closing Comments Jerry Radich, MD, Fred Hutch Cancer Center

Speakers

Jerald Radich, MD
Director, Molecular Oncology Lab
Fred Hutchinson Cancer Research Center
View Profile
Member, Clinical Research Division
Director, Molecular Oncology Lab
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Research Center
Professor of Medicine
University of Washington School of Medicine
Dr. Jerald Radich is a Member of the Clinical Research Division, Director of the Molecular Oncology Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group. He was the inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, and a past member of the Board of Scientific Counselors of the National Institute of Health Genome Research Institute. He is the past-chair of the CML Committee of the National Comprehensive Cancer Network, a member of the European Leukemia Network CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. He currently leads the Laboratory Committee of the NCI AML Precision Medicine Initiative (“myeloMATCH”) and leads the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich’s laboratory research centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. In addition, the CLIA Molecular Oncology Lab provides the molecular diagnostic support for many institutional, U.S. Intergroup, international, and pharmaceutical trials, including the NCI Precision Medicine Initiative in AML (myeloMATCH). He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring CML in the developing world, and the International CML Foundation Janet Rowley Award in 2023 for his work on the biology of CML.
Cecilia Yeung, MD
Medical Director
Clinical Testing Labs
Fred Hutch Cancer Institute
View Profile
Professor
Translational Science and Therapeutics Division, Fred Hutch
Medical Director
Clinical Testing Labs, Fred Hutch
Dr. Cecilia Yeung’s research focuses on genomic changes, clonal evolution, and epigenetic control of gene expression in myeloid neoplasms (MDS, MPN and AML) and she has developed research expertise in biomarker and mutation profiling of cancers with cross correlation of clinical and pathology data (including histology, immunohistochemistry, flow cytometry, cytogenetics and clinical molecular testing). Dr. Yeung’s goal is to help all patients around the world get to appropriate treatments faster to enjoy better outcomes and improve survival. Her vision and personal expertise in molecular pathology has led to the pursuit of novel molecular diagnostic platforms and bioinformatics solutions that push the limits for faster, simpler, more accurate, and more cost-effective diagnostic tools.
Learn more about Dr. Yeung.